🏛️ Verified NIH Record • Updated 2025-09-26
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer (NCT03563248)
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Massachusetts General Hospital
🩺 Plain-English Summary (8th-Grade Level)
This research study is studying a combination of interventions as a possible treatment for pancreatic tumor. The interventions involved in this study are: * FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin * Losartan * Nivolumab * Radiation Therapy * Surgery
Who can join: Review the eligibility criteria below.
Location: University of Colorado Cancer Center — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- University of Colorado Cancer Center — Aurora, Colorado
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- The Johns Hopkins Hospital — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Newton Wellesley Hospital — Newton, Massachusetts
- New York University Langone Medical Center — New York, New York
- MD Anderson Cancer Center — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Cancer
- A Study of the Life Changes Experienced by Patients With Pancreatic Cancer — New York, New York
- Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer — Baltimore, Maryland
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma — Hartford, Connecticut
- Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer — Philadelphia, Pennsylvania
- Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer — Basking Ridge, New Jersey
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas — Baltimore, Maryland
Explore by condition: All Pancreatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.